EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myocardial Perfusion in Cardiac Amyloidosis

Liza Chacko, Tushar Kotecha, Adam Ioannou, Niket Patel, Ana Martinez-Naharro, Yousuf Razvi, Rishi Patel, Paolo Massa, Lucia Venneri, James Brown, Aldostefano Porcari, Kristopher Knott und 18 weitere

European Journal of Heart Failure · 01.03.2024 · 26 (3) · 598-609

DOI: 10.1002/ejhf.3137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 21.01.2024. Verfasst von Liza Chacko und 29 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK. Hauptthemen laut MEDLINE: Coronary Circulation, Cardiomyopathies, Amyloidosis. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cardiac involvement is the main driver of clinical outcomes in systemic amyloidosis and preliminary studies support the hypothesis that myocardial ischaemia contributes to cellular damage. The aims of this study were to assess the presence and mechanisms of myocardial ischaemia using cardiovascular magnetic resonance (CMR) with multiparametric mapping and histopathological assessment. Methods and results Ninety-three patients with cardiac amyloidosis (CA) (light-chain amyloidosis n = 42, transthyretin amyloidosis n = 51) and 97 without CA (three-vessel coronary disease [3VD] n = 47, unobstructed coronary arteries n = 26, healthy volunteers [HV] n = 24) underwent quantitative stress perfusion CMR with myocardial blood flow (MBF) mapping. Twenty-four myocardial biopsies and three explanted hearts with CA were analysed histopathologically. Stress MBF was severely reduced in patients with CA with lower values than patients with 3VD, unobstructed coronary arteries and HV (CA: 1.04 ± 0.51 ml/min/g, 3VD: 1.35 ± 0.50 ml/min/g, unobstructed coronary arteries: 2.92 ± 0.52 ml/min/g, HV: 2.91 ± 0.73 ml/min/g; CA vs. 3VD p = 0.011, CA vs. unobstructed coronary arteries p < 0.001, CA vs. HV p < 0.001). Myocardial perfusion abnormalities correlated with amyloid burden, systolic and diastolic function, structural parameters and blood biomarkers (p < 0.05). Biopsies demonstrated abnormal vascular endothelial growth factor staining in cardiomyocytes and endothelial cells, which may be related to hypoxia conditions. Amyloid infiltration in intramural arteries was associated with severe lumen reduction and severe reduction in capillary density.

Conclusion

Cardiac amyloidosis is associated with severe inducible myocardial ischaemia demonstrable by histology and CMR stress perfusion mapping. Histological evaluation indicates a complex pathophysiology, where in addition to systolic and diastolic dysfunction, amyloid infiltration of the epicardial arteries and disruption and rarefaction of the capillaries play a role in contributing to myocardial ischaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary CirculationCardiomyopathiesAmyloidosisHumansMaleFemaleMiddle AgedAgedMagnetic Resonance Imaging, CineMyocardiumImmunoglobulin Light-chain AmyloidosisMyocardial IschemiaAmyloid Neuropathies, FamilialMyocardial Perfusion ImagingCoronary VesselsBiopsy

Stichwörter der Autor:innen

AmyloidosisExtracellular volumeInfiltrationIschaemiaMagnetic resonance imagingPerfusion

Autor:innen und Institutionen

  • National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK.
  • Royal Free Hospital NHS Foundation Trust, London, UK.
  • Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, IRCCS Sant'Orsola Hospital, Bologna, Italy.
  • Institute of Cardiovascular Science, University College London, London, UK.
  • Barts Heart Centre, London, UK.
  • Division of Cardiovascular Sciences, University of Navarra, Pamplona, Spain.

Förderung

  • British Heart Foundation

Zitieren

APA

Chacko, L., Kotecha, T., Ioannou, A., Patel, N., Martinez-Naharro, A., Razvi, Y., Patel, R., Massa, P., Venneri, L., Brown, J., Porcari, A., Knott, K., Manisty, C., Knight, D., Lockie, T., Rakhit, R., Lachmann, H., Wechelakar, A., Whelan, C., …, & Fontana, M. (2024). Myocardial Perfusion in Cardiac Amyloidosis. European Journal of Heart Failure, 26(3), 598-609. https://doi.org/10.1002/ejhf.3137

Vancouver

Chacko L, Kotecha T, Ioannou A, Patel N, Martinez-Naharro A, Razvi Y, et al. Myocardial Perfusion in Cardiac Amyloidosis. European Journal of Heart Failure. 2024;26(3):598-609. doi:10.1002/ejhf.3137

BibTeX
@article{Chacko2024,
  author = {Chacko, Liza and Kotecha, Tushar and Ioannou, Adam and Patel, Niket and Martinez-Naharro, Ana and Razvi, Yousuf and Patel, Rishi and Massa, Paolo and Venneri, Lucia and Brown, James and Porcari, Aldostefano and Knott, Kristopher and Manisty, Charlotte and Knight, Daniel and Lockie, Tim and Rakhit, Roby and Lachmann, Helen and Wechelakar, Ashutosh and Whelan, Carol and Ponticos, Markella and Moon, James and González, Arantxa and Gilbertson, Janet and Riefolo, Mattia and Leone, Ornella and Xue, Hui and Hawkins, Philip and Kellman, Peter and Gillmore, Julian and Fontana, Marianna},
  title = {Myocardial Perfusion in Cardiac Amyloidosis},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {3},
  pages = {598--609},
  doi = {10.1002/ejhf.3137}
}
Kostenlos starten →